



Amendments to the Claims

## WHAT IS CLAIMED IS:

1. (Currently Amended) A compound having a formula-formula I,



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:



b) — a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S;

c) — C<sub>2</sub>-C<sub>6</sub> cycloalkyl;

d) — aliphatic group; or

e) — heterocyclyl;

wherein aryl, heteroaryl, cycloalkyl, heterocyclyl and aliphatic group being optionally substituted with one or more groups independently selected from R<sup>8</sup>;

D<sub>a</sub> and D<sub>b</sub> are each independently:

a bond or

—[C(R<sup>c</sup>)(R<sup>d</sup>)]<sub>n</sub>, wherein R<sup>c</sup> and R<sup>d</sup> are each independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aryl;

E is: S, O, or NR<sup>10</sup>; wherein R<sup>10</sup> is hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl;

s is 1, 2, 3, 4, 5, or 6;


Q is: —C(O)OR<sup>5</sup> or R<sup>5A</sup>;

X is:  $\text{NR}^6\text{C}[\text{O}]_p$ ,

$$\text{NR}^6\text{S}(\text{O})_2,$$
$$\text{C}[\text{O}]_p, \text{NR}^6,$$
$$\text{S(O)}_2\text{NR}^6 \text{ or}$$

NR<sup>7</sup>;

Y is: a bond, CH<sub>2</sub>, S or O;



n and r are each independently: 1, 2, 3 or 4;

q is: 1, 2, 3, 4 or 5;

p is: 1 or 2;

R<sup>1</sup> and R<sup>2</sup> are each independently: hydrogen, C<sub>1</sub>–C<sub>6</sub> alkyl, halo or haloalkyl;

$R^3$  and  $R^4$  are each independently:

hydrogen,

halo,

C<sub>1</sub>-C<sub>6</sub> alkyl,


C<sub>1</sub>-C<sub>6</sub> alkoxy or

aryloxy;

R<sup>3</sup> and R<sup>4</sup> are together a 3- to 6- membered carbocyclyl or heterocyclyl;

R<sup>5</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aminoalkyl;

R<sup>5A</sup> is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,



$R^6$  is each independently:

hydrogen,  
 $C_1$ - $C_{12}$  alkyl,  
 arylalkyl,  
 $C_3$ - $C_8$  cycloalkyl, or  
 $(CH_2)_nC(O)aryl$ ,

wherein alkyl, arylalkyl and cycloalkyl group being optionally substituted with one or more groups independently selected from  $R^8$ ;

$R^7$  is: hydrogen,  
 acyl, or  
 sulfonyl;

$R^8$  and  $R^{8a}$  are each independently:

hydrogen,  
 $C_1$ - $C_6$  alkyl,  
 $C_1$ - $C_6$  alkoxy,  
 nitro,  
 cyano,  
 halo,  
 haloalkyl,  
 haloalkyloxy,  
 aryl,  
 heteroaryl,  
 benzyl,

aryloxy,

SR<sup>9</sup>,

S[O]<sub>p</sub>R<sup>9</sup> or

C[O]<sub>p</sub>R<sup>9</sup>; wherein when A is phenyl and when R<sup>8</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, nitro, cyano, halo, haloalkyl, haloalkyloxy, aryl, heteroaryl, benzyl, aryloxy, SR<sup>9</sup>, S[O]<sub>p</sub>R<sup>9</sup> and C[O]<sub>p</sub>R<sup>9</sup>, then R<sup>8</sup> is monosubstituted in the 4 position or disubstituted in 2 and 4 positions, or trisubstituted in 2, 4, and 6 positions of phenyl ring relative to -D<sub>b</sub>- and


R<sup>9</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, or C<sub>3</sub>-C<sub>8</sub> cycloalkyl.

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Currently Amended) The compound of ~~Claim 1~~ Claim 3, wherein the compound is structural formula III,



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

Y is: O or CH<sub>2</sub>;

R<sup>1</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>4</sub> alkyl;


R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>6</sup>, R<sup>c</sup> and R<sup>d</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

(R<sup>8</sup>)<sub>1</sub> and (R<sup>8</sup>)<sub>2</sub> are each independently: hydrogen, halo, haloalkyl or haloalkyloxy, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy or SR<sup>9</sup>;

R<sup>6</sup> is: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and

R<sup>9</sup> is: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>3</sub>-C<sub>6</sub> cycloalkyl.

6. (Previously Presented) The compound of Claim 5, wherein the compound is structural formula IV,



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:


$R^1$  and  $R^2$  are each independently: hydrogen, halo or  $C_1$ - $C_4$  alkyl;

$R^c$ ,  $R^d$  and  $R^6$  are each independently: hydrogen or methyl; and

$(R^8)_1$  and  $(R^8)_2$  are each independently:

hydrogen, F, Cl, Br, OMe,  $CF_3$ ,  $OCF_3$ ,  $SCH_3$ ,  $NO_2$ , cyano, methyl, ethyl, isobutyl, isopropyl or tert-butyl.

7. (Previously Presented) The compound of Claim 6, wherein the compound is structural formula V,



or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:


$R^1$  and  $R^2$  are each independently: hydrogen, methyl, ethyl or fluoro; and

$(R^8)_1$  and  $(R^8)_2$  are each independently:

hydrogen, F, Cl, Br, OMe,  $CF_3$ ,  $OCF_3$ ,  $SCH_3$ ,  $NO_2$ , cyano, methyl, ethyl, isobutyl, isopropyl or tert-butyl.

8. (Canceled)

9. (Currently Amended) The compound of ~~Claim 3~~Claim 1, wherein the compound is structural formula VII,



VII

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

$R^1$  and  $R^2$  are each independently: hydrogen, halo or  $C_1$ - $C_4$  alkyl;


$R^6$  is: hydrogen or  $C_1$ - $C_4$  alkyl;

$R^8$  is: hydrogen, halo, haloalkyl or haloalkyloxy, cyano, nitro,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy or  $SR^9$ ;  
and

$R^9$  is: hydrogen or  $C_1$ - $C_4$  alkyl or  $C_3$ - $C_6$  cycloalkyl.

10. (Canceled)

11. (Previously Presented) The compound of Claim 1, wherein the compound is structural formula VIII,




VIII

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

$q$  is 1, 2, 3 or 4; and

$E$  is S, O or  $NR^{10}$  wherein  $R^{10}$  is hydrogen or  $C_1$ - $C_4$  alkyl.

12. (Previously Presented) The compound of Claim 11, wherein the compound is structural formula IX,



## IX

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

Y is: O or CH<sub>2</sub>;

E is: S, O, NH or NCH<sub>3</sub>, NCH<sub>2</sub>CH<sub>3</sub>;

R<sup>1</sup> is: hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, halo or haloalkyl;

R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>6</sup>, R<sup>c</sup> and R<sup>d</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

(R<sup>8</sup>)<sub>1</sub> and (R<sup>8</sup>)<sub>2</sub> are each independently: hydrogen, halo, haloalkyl, haloalkyloxy, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> alkoxy; and


R<sup>8</sup> is: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl.

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Previously Presented) The compound of Claim 12, wherein the compound is structural formula XIII,



XIII

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

Y is: O or CH<sub>2</sub>;

R<sup>1</sup> is: hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, halo or haloalkyl;

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup>, R<sup>c</sup> and R<sup>d</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>8</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and


(R<sup>8</sup>)<sub>1</sub> is: hydrogen, halo, haloalkyl or haloalkyloxy, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> alkoxy.

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Previously Presented) The compound of Claim 1, wherein the compound is structural formula XVI,




**XVI**

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

n is 1, 2, 3, or 4.

21. (Original) The compound of Claim 20, wherein Y is O or CH<sub>2</sub>; R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>c</sup> and R<sup>d</sup> are each independently hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; n is 1 or 2; R<sup>6</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or arylalkyl; and R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkoxy, halo or haloalkyl.

22. (Previously Presented) The compound of Claim 1, wherein the compound is structural formula XVII,



**XVII**


or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

R<sup>8a</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or aryl; and s is 1, 2, 3, 4, 5 or 6.

23. (Canceled)



24. (Previously Presented) The compound of Claim 1, wherein the compound having a structural formula XIX,



**XIX**

or a pharmaceutically acceptable salt or stereoisomer thereof.

25. (Currently Amended) The compound of Claim 24, wherein Q is COOH; R<sup>7</sup> is hydrogen, methanesulfonyl or acetyl; and R<sup>c</sup> and R<sup>d</sup> are each hydrogen.

26. (Currently Amended) A compound of Claim 1 selected from the group consisting of:

No	Structure	Name
1		2-(4-{3-[(2-Chloro-4-trifluoromethyl-benzoylamino)-methyl]-5-fluoro-phenoxy}-2-methyl-phenoxy)-2-methyl-propionic acid
2		3-[4-(3-{[(5-Chloro-1H-indole-2-carbonyl)-amino]-methyl}-5-fluoro-phenoxy)-2-methyl-phenyl]-propionic acid
3		2-(4-{3-Fluoro-5-[1-(2-methyl-4-trifluoromethyl-benzoylamino)-ethyl]-phenoxy}-2-methyl-phenoxy)-2-methyl-propionic acid (isomer 1)
4		2-[4-(3-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-carbonyl)-amino]-methyl}-5-methyl-phenoxy)-2-methyl-phenoxy]-2-methyl-propionic acid

No	Structure	Name
5		( R )-3-[4-(3-{1-[(5-Chloro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-ethyl}-5-fluorophenoxy)-2-methyl-phenyl]-propionic acid
6		3-(2-Ethyl-4-{3-fluoro-5-[(2-methyl-4-trifluoromethyl-benzoylamino)-methyl]-phenoxy}-phenyl)-propionic acid
7		2-(4-{3-[(2-Fluoro-4-trifluoromethyl-benzoylamino)-methyl]-5-methyl-phenoxy}-2-methyl-phenoxy)-2-methyl-propionic acid
8		( R )-2-[4-(3-{[(5-Chloro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-methyl}-5-methyl-phenoxy)-2-methyl-phenoxy]-2-methyl-propionic acid
9		3-[4-(3-Fluoro-5-{[(5-fluoro-3-methyl-1H-indole-2-carbonyl)-amino]-methyl}-phenoxy)-2-methyl-phenyl]-propionic acid
10		2-[4-(3-Fluoro-5-{[(5-fluoro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-methyl}-phenoxy)-2-methyl-phenoxy]-2-methyl-propionic acid
11		( R )-3-[4-(3-{1-[(5-Fluoro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-ethyl}-5-methyl-phenoxy)-2-methyl-phenyl]-propionic acid

No	Structure	Name
12		2-Methyl-2-(2-methyl-4-{3-[(2-methyl-4-trifluoromethyl-benzoylamino)-methyl]-phenoxy}-phenoxy)-propionic acid
13		2-(4-{3-Fluoro-5-[(2-methyl-4-trifluoromethyl-benzoylamino)-methyl]-phenoxy}-2-methyl-phenoxy)-2-methyl-propionic acid
14		( R ) -3-[4-(3-Fluoro-5-{1-[(5-fluoro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-ethyl}-phenoxy)-2-methyl-phenyl]-propionic acid
15		3-[4-(3-{[(5-Chloro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-methyl}-5-fluoro-phenoxy)-2-methyl-phenyl]-propionic acid
16		3-[4-(3-{[(5-Chloro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-methyl}-phenoxy)-2-methyl-phenyl]-propionic acid
17		3-[2-Ethyl-4-(3-fluoro-5-{[(5-fluoro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-methyl}-phenoxy)-phenyl]-propionic acid
18		3-(4-{3-[(2-Chloro-4-trifluoromethyl-benzoylamino)-methyl]-5-methyl-phenoxy}-2-ethyl-phenyl)-propionic acid

27. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1 or of Claim 1 or a pharmaceutically acceptable salt.

- 28. (Canceled)
- 29. (Canceled.)
- 30. (Canceled.)
- 31. (Canceled.)
- 32. (Canceled.)
- 33. (Canceled.)
- 34. (Canceled.)
- 35. (Canceled.)
- 36. (Canceled.)
- 37. (Canceled.)
- 38. (Canceled.)
- 39. (Currently Amended) A method for lowering blood-glucose in a mammal comprising the step of administering an effective amount of a compound of Claim 1.
- 40. (Canceled)
- 41. (Canceled)
- 42. (Canceled)
- 43. (Canceled)
- 44. (Canceled)
- 45. (Canceled)